I. Dussault

E. Felip, L. Paz-Ares, B. Cho, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Dual inhibition of TGF‐β and PD‐L1: a novel approach to cancer treatment

M. Barcellos-Hoff, J. Schlom, A. Moustakas, 2021, Molecular oncology.

Decline in natural killer cell-mediated immunosurveillance in aging mice — a consequence of reduced cell production and tumor binding capacity

I. Dussault, Sandra C. Miller, S. C. Miller, 1994, Mechanisms of Ageing and Development.

Differential regulation of the N-myc proto-oncogene by ROR alpha and RVR, two orphan members of the superfamily of nuclear hormone receptors

V. Giguère, I. Dussault, 1997, Molecular and cellular biology.

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

C. Borel, P. A. Rolfe, C. Ihling, 2022, Frontiers in Oncology.

Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.

E. Felip, L. Paz-Ares, B. Cho, 2018 .

Selection of the recommended phase 2 dose (RP2D) for M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1.

Y. Vugmeyster, Akash Khandelwal, J. Gulley, 2018 .

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with heavily pretreated CRC: Preliminary results from a phase I trial.

Edward J. Kim, H. Lenz, S. Kopetz, 2018 .

Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.

K. Rex, Matthew R. Lee, C. Dominguez, 2012, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of potent c-Met inhibitors.

Yuan Cheng, K. Rex, A. Coxon, 2008, Journal of medicinal chemistry.

c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations*

K. Rex, A. Coxon, A. Tasker, 2008, Journal of Biological Chemistry.

HGF-and c-Met-targeted drugs : hopes, challenges and their future in cancer therapy

A. Coxon, T. Burgess, P. Kaplan-Lefko, 2006 .

Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism.

E. Fernandez, B. M. Forman, M. Sherman, 2004, Molecular cell.

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.

T. Bush, Marc Payton, Grace Chung, 2010, Cancer research.

Prostaglandins and fatty acids regulate transcriptional signaling via the peroxisome proliferator activated receptor nuclear receptors.

B. M. Forman, I. Dussault, Isabelle Dussault, 2000, Prostaglandins & other lipid mediators.

In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models

K. Rex, A. Coxon, M. Damore, 2016, Molecular Cancer Therapeutics.

The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux

B. M. Forman, T. Synold, I. Dussault, 2001, Nature Medicine.

Therapeutics , Targets , and Chemical Biology Preclinical Evaluation of AMG 900 , a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines

T. Bush, Marc Payton, Grace Chung, 2010 .

The nuclear receptor PXR: a master regulator of "homeland" defense.

B. M. Forman, I. Dussault, 2002, Critical reviews in eukaryotic gene expression.

Small-molecule Kinase Inhibitor with Antitumor Activity Identification of a Novel Recepteur D'origine Nantais/c-met Material Supplementary Cited Articles Citing Articles E-mail Alerts Identification of a Novel Recepteur D'origine Nantais/c-met Small-molecule Kinase Inhibitor with Antitumor Activity

K. Rex, A. Coxon, T. Burgess, 2022 .

c-Met inhibitors with different binding modes: Two is better than one

S. Bellon, I. Dussault, Steven F Bellon, 2008, Cell cycle.

High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide

E. Schmidt, J. O'neil, R. Cristescu, 2016, Molecular Cancer Therapeutics.

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer

M. Kudo, M. Osada, M. Ikeda, 2020, Journal for immunotherapy of cancer.

Orphan nuclear receptor RORα-deficient mice display the cerebellar defects of staggerer

V. Giguère, I. Dussault, J. Bader, 1998, Mechanisms of Development.

Peptide Mimetic HIV Protease Inhibitors Are Ligands for the Orphan Receptor SXR*

B. M. Forman, Min Lin, T. Synold, 2001, The Journal of Biological Chemistry.

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort

K. Kelly, E. Felip, N. Isambert, 2021, Targeted Oncology.

Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma

K. Kolibaba, M. Weller, A. Scott, 2021, Neuro-oncology advances.

Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.

K. Rex, A. Coxon, T. Burgess, 2008, Cancer research.

Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma

L. Terracciano, P. A. Rolfe, C. Ihling, 2019, Front. Med..

From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer.

S. Bellon, I. Dussault, 2009, Anti-cancer agents in medicinal chemistry.

Discovery of MK-4688: an Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction.

G. Scapin, M. Altman, X. Fradera, 2021, Journal of medicinal chemistry.

STK33 kinase activity is nonessential in KRAS-dependent cancer cells.

J. McCarter, J. Zondlo, R. Kurzeja, 2011, Cancer research.

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia

M. Osada, K. Muro, Chia‐Chi Lin, 2021, Targeted Oncology.

Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer

Y. Bang, Yoon-Koo Kang, M. Osada, 2020, Clinical Cancer Research.

Identification of Gene-selective Modulators of the Bile Acid Receptor FXR*

Jasmine Chen, B. M. Forman, R. Chandraratna, 2003, The Journal of Biological Chemistry.

Abstract 728: AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models

K. Rex, A. Coxon, R. Radinsky, 2014 .

A Structural Model of the Constitutive Androstane Receptor Defines Novel Interactions That Mediate Ligand-Independent Activity

B. M. Forman, J. Termini, M. Sherman, 2002, Molecular and Cellular Biology.

Discovery of (R)-6-(1-(8-Fluoro-6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl)ethyl)-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one (AMG 337), a Potent and Selective Inhibitor of MET with High Unbound Target Coverage and Robust In Vivo Antitumor Activity.

K. Rex, A. Coxon, D. Whittington, 2016, Journal of medicinal chemistry.

Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2015, Journal of medicinal chemistry.

Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors.

K. Rex, D. Whittington, S. Bellon, 2012, Bioorganic & Medicinal Chemistry Letters.

Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).

M. Ahn, T. Mok, E. Felip, 2019, Journal of Clinical Oncology.

Updated results of M7824 (MSB0011359C): A bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC.

L. Paz-Ares, B. Cho, M. Di Nicola, 2018, Annals of Oncology.

Effect on leukemia cell numbers of in vivo administration of immunotherapeutic agents is age-dependent.

S. Miller, I. Dussault, 1996, Oncology.

Stimulation of natural killer cell numbers but not function in leukemic infant mice: a system primed in infancy allows survival in adulthood.

S. Miller, I. Dussault, 1993, Natural immunity.

M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial.

M. Osada, M. Ikeda, D. Oh, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

P37 Phase 1 evaluation of bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1, in cervical cancer

L. Paz-Ares, W. Edenfield, F. Braiteh, 2019, International Journal of Gynecological Cancer.

Therapeutics , Targets , and Chemical Biology STK 33 Kinase Activity Is Nonessential in KRAS-Dependent Cancer Cells

J. McCarter, J. Zondlo, R. Kurzeja, 2011 .

Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors.

K. Rex, K. Shah, S. Bellon, 2009, Bioorganic & medicinal chemistry letters.